{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099404","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.622760+00:00","generated_at":"2026-05-17T23:45:11.152549+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD","bullets":["Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.","Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.","Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.","Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.","20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099404","json":"https://secwatch.observer/filing/0000950170-25-099404.json","markdown":"https://secwatch.observer/filing/0000950170-25-099404.md","text":"https://secwatch.observer/filing/0000950170-25-099404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/0000950170-25-099404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:45:11.152549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}